New Retina Radio by Eyetube

Co-hosts Justin C. Muste, MD, and David Fell, MD, discuss the endophthalmitis endgame with Jordan Deaner, MD, a retina specialist at Wills Eye Hospital, and Wills Eye retina fellows Collin Richards, MD, and Erik Massenzio, MD. They share the best timing and treatment approach to patients who present with post-cataract and post-injection endophthalmitis. Shared cases help illustrate when to tap-and-inject (you will never regret doing it, but you might regret not doing it), when vitrectomy is warranted, the challenges of fungal endophthalmitis, and more.

Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.

The debates at AAO Retina Subspecialty Day have a reputation for examining unresolved issues. Where did the debate on whether wet AMD tolerates fluid land? Avni Finn, MD, joined the show to recap her side of the wet AMD fluid debate—and shared what the opposite side had to argue, too. How well does she buy her own argument?



And Darius Moshfeghi, MD, joins the show to share findings from the SOL-1 study examining OTX-TKI (Ocular Therapeutix) for wet AMD. What did the researchers find? And how did the study authors leverage AI to simulate real-world treatment activity? Join us on this episode to find out.

Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.